Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies
Mohamed L. Sorror(University of Washington Medical Center), Rainer Storb(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Marco Mielcarek(Fred Hutch Cancer Center), David G. Maloney(Fred Hutch Cancer Center), Wolfgang Bethge(University of Tübingen), Firoozeh Sahebi(City Of Hope National Medical Center), Parameswaran Hari(Medical College of Wisconsin), Benedetto Bruno(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Dietger Niederwieser(Leipzig University of Applied Sciences), Thomas R. Chauncey(City Of Hope National Medical Center), Amelia Langston(CancerCare Manitoba), Barry E. Storer(City Of Hope National Medical Center), Ginna G. Laport(Stanford Blood Center), Richard T. Maziarz(Oregon Health & Science University), Kai Hübel(University Hospital Cologne), Brenda M. Sandmaier(University of Washington), Andrew M. Yeager(University of Arizona), Peter A. McSweeney(Colorado Blood Cancer Institute), Lars L. Vindeløv(University of Copenhagen), Finn Bo Petersen(Intermountain Healthcare), Edward Agura(Baylor University), Karl G. Blume(City Of Hope National Medical Center), Georg‐Nikolaus Franke(University Hospital Leipzig), Michael A. Pulsipher(Primary Children's Hospital), Michael B. Maris(Colorado Blood Cancer Institute), George E. Georges(Northwestern University)
Cited by 320
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k